---
title: "STAT+: GSK touts lung cancer data from two drugs"
description: "Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news from The Readout"
author: "Meghana Keshavan"
section: health
published: 2026-09-15T03:45:13.354129+00:00
canonical: https://valorandventures.media/article/79a49a73-baee-4a97-bc24-7601dbb83fbf
publisher: "Valor & Ventures Media"
source: "STAT News"
source_url: https://www.statnews.com/2026/09/14/biotech-news-gsk-touts-lung-cancer-data-from-two-drugs/?utm_campaign=rss
access: free
---

# STAT+: GSK touts lung cancer data from two drugs

*Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news from The Readout*

## Executive Summary

According to a report by STAT News, the pharmaceutical and biotechnology sectors are witnessing a series of major clinical updates that highlight both the breakthroughs and the inherent risks of drug development. Published on September 14, 2026, by journalist Meghana Keshavan, the dispatch outlines pivotal updates from industry giants and emerging firms alike. Chief among these developments is the British drugmaker GSK, which has publicized positive data regarding two of its lung cancer treatments. Simultaneously, the landscape of psychiatric and neurological medicine is seeing movement with Definium's latest clinical results, while established leader AstraZeneca has encountered a significant hurdle in its oncology pipeline. The report from STAT News notes that GSK is highlighting promising clinical results for two separate lung cancer therapeutics. While specific trial metrics were not detailed in the original reporting, the company’s decision to promote these data points underscores its ongoing strategic focus on expanding its oncology portfolio and securing a larger share of the highly competitive lung cancer market. In a separate and highly watched therapeutic area, Definium has announced late-stage clinical trial results for its lysergic acid diethylamide (LSD) treatment. This milestone represents a critical step forward in the clinical exploration of psychedelic-assisted therapies, which are increasingly viewed as potential disruptors in mental health frameworks. Conversely, the high-risk nature of biopharmaceutical innovation is illustrated by AstraZeneca's recent setback. The outlet reports that a key trial for one of AstraZeneca's breast cancer drug candidates has failed to meet its necessary benchmarks. Such clinical trial failures represent major strategic challenges for multinational pharmaceutical corporations, often resulting in redirected research budgets, altered market projections, and fluctuating investor confidence. Together, these contrasting outcomes from GSK, Definium, and AstraZeneca demonstrate the volatile, dual-sided reality of clinical research where immense scientific triumphs and costly setbacks routinely coexist. For executives, founders, and leaders within the Valor & Ventures community, these developments offer vital lessons in risk management, strategic diversification, and the evolving frontiers of medicine. The success of GSK's lung cancer assets and the advancement of Definium's psychedelic therapy illustrate how pioneering research can open new market segments and therapeutic avenues. Meanwhile, the clinical failure experienced by AstraZeneca serves as a sobering reminder of the operational and financial hazards inherent in high-stakes research and development. Observing how these organizations navigate these clinical trial milestones provides critical insights for civic and corporate leaders managing complex portfolios in highly regulated, science-driven industries.

## Article

Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news from The Readout
— Meghana Keshavan · STAT News · Photo: Leon Neal/Getty Images
Read the full report at STAT News: https://www.statnews.com/2026/09/14/biotech-news-gsk-touts-lung-cancer-data-from-two-drugs/?utm_campaign=rss

## Citations

1. Claim: “Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news from The Readout” — [STAT News](https://www.statnews.com/2026/09/14/biotech-news-gsk-touts-lung-cancer-data-from-two-drugs/?utm_campaign=rss) — Originating report.

---

Originally published by STAT News: https://www.statnews.com/2026/09/14/biotech-news-gsk-touts-lung-cancer-data-from-two-drugs/?utm_campaign=rss